 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
12-5-2023
Insider Buy |
Christopher S. Boerner
Chief Executive Officer |
$49.78
CAGR »
|
$99,560.00
2,000 shares |
11-28-2023
Insider Buy |
Christopher S. Boerner
Chief Executive Officer |
$48.86
CAGR »
|
$150,049.06
3,071 shares |
11-20-2023
Insider Buy |
Theodore R. Samuels II
Director |
$49.81
CAGR »
|
$423,385.00
8,500 shares |
6-15-2020
Insider Buy |
Dinesh C. Paliwal
Director |
$54.50
CAGR »
|
$499,983.00
9,174 shares |
12-4-2019
Insider Buy |
Michael W. Bonney
Director |
$58.90
CAGR »
|
$5,183.20
88 shares |
7-31-2019
Insider Buy |
Robert J. Bertolini
Director |
$44.72
CAGR »
|
$491,920.00
11,000 shares |
5-16-2019
Insider Buy |
Theodore R. Samuels II
Director |
$47.29
CAGR »
|
$236,440.00
5,000 shares |
4-30-2018
Insider Buy |
Dinesh C. Paliwal
Director |
$52.40
CAGR »
|
$499,896.00
9,540 shares |
12-15-2017
Insider Buy |
Theodore R. Samuels II
Director |
$62.30
CAGR »
|
$249,187.20
4,000 shares |
8-2-2017
Insider Buy |
Theodore R. Samuels II
Director |
$55.94
CAGR »
|
$335,622.00
6,000 shares |
2-27-2017
Insider Buy |
Theodore R. Samuels II
Director |
$56.77
CAGR »
|
$681,240.00
12,000 shares |
2-17-2011
Insider Buy |
James M. Cornelius
Director |
$25.73
CAGR »
|
$23,159.88
900 shares |
Also See: Institutional Holders of BMY
Also See: SEC filings
Below we present the annualized performance delivered by Bristol-Myers Squibb stock since 12-5-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Bristol-Myers Squibb insider buying occurred is the ultimate
test of whether insiders were right about BMY being a good buy.
Growth of $10,000.00
With Dividends Reinvested
|
| Start date: |
12/06/2023 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$49.88 |
|
| End price/share: |
$48.30 |
|
| Starting shares: |
200.48 |
|
| Ending shares: |
205.16 |
|
| Dividends reinvested/share: |
$1.20 |
|
| Total return: |
-0.91% |
|
| Annualized Gain: |
-2.49% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$9,909.00 |
|
| Years: |
0.36 |
|
| |
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/06/2023 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$49.88 |
|
| End price/share: |
$48.30 |
|
| Dividends collected/share: |
$1.20 |
|
| Total return: |
-0.76% |
|
| Annualized Gain: |
-2.09% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$9,924.00 |
|
| Years: |
0.36 |
|
Bristol-Myers Squibb Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Bristol-Myers Squibb insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding BMY
|
|
Free BMY Email Alerts:
